There have been three clinical trials for Repotrectinib: One in phase I for NSCLC (NCT 04772235) and two clinical trials in phase II for pediatric patients harboring Alk, Ros1 or Ntrk1-3 mutations in solid tumors, lymphomas and central nervous system tumors (NCT 04094610), and adult patients with advanced solid malignancies harboring an Alk, Ros1, Ntrk1, Ntrk2 or Ntrk3 gene rearrangement (NCT 03093116). The gene discussed is ALK; the disease is lymphoma.